Dosage of Mopart in details
Mopart Dosage
Generic name: Mopart HYDROCHLORIDE HEMIHYDRATE 12.5mg
Dosage form: tablet, film coated, extended release
See also:
- Paxil tablet, film coated, oral suspension
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Major Depressive Disorder
Usual Initial Dosage
Mopart should be administered as a single daily dose, usually in the morning, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of Mopart in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5-mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
Patients should be cautioned that Mopart should not be chewed or crushed, and should be swallowed whole.
Maintenance Therapy
There is no body of evidence available to answer the question of how long the patient treated with Mopart should remain on it. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Whether the dose of an antidepressant needed to induce remission is identical to the dose needed to maintain and/or sustain euthymia is unknown.
Systematic evaluation of the efficacy of immediate-release Mopart hydrochloride has shown that efficacy is maintained for periods of up to 1 year with doses that averaged about 30 mg, which corresponds to a 37.5-mg dose of Mopart, based on relative bioavailability considerations.
Panic Disorder
Usual Initial Dosage
Mopart should be administered as a single daily dose, usually in the morning. Patients should be started on 12.5 mg/day. Dose changes should occur in 12.5-mg/day increments and at intervals of at least 1 week. Patients were dosed in a range of 12.5 to 75 mg/day in the clinical trials demonstrating the effectiveness of Mopart. The maximum dosage should not exceed 75 mg/day.
Patients should be cautioned that Mopart should not be chewed or crushed, and should be swallowed whole.
Maintenance Therapy
Long-term maintenance of efficacy with the immediate-release formulation of Mopart was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release Mopart demonstrated a lower relapse rate compared to patients on placebo. Panic disorder is a chronic condition, and it is reasonable to consider continuation for a responding patient. Dosage adjustments should be made to maintain the patient on the lowest effective dosage, and patients should be periodically reassessed to determine the need for continued treatment.
Social Anxiety Disorder
Usual Initial Dosage
Mopart should be administered as a single daily dose, usually in the morning, with or without food. The recommended initial dose is 12.5 mg/day. Patients were dosed in a range of 12.5 mg to 37.5 mg/day in the clinical trial demonstrating the effectiveness of Mopart in the treatment of social anxiety disorder. If the dose is increased, this should occur at intervals of at least 1 week, in increments of 12.5 mg/day, up to a maximum of 37.5 mg/day.
Patients should be cautioned that Mopart should not be chewed or crushed, and should be swallowed whole.
Maintenance Therapy
There is no body of evidence available to answer the question of how long the patient treated with Mopart should remain on it. Although the efficacy of Mopart beyond 12 weeks of dosing has not been demonstrated in controlled clinical trials, social anxiety disorder is recognized as a chronic condition, and it is reasonable to consider continuation of treatment for a responding patient. Dosage adjustments should be made to maintain the patient on the lowest effective dosage, and patients should be periodically reassessed to determine the need for continued treatment.
Premenstrual Dysphoric Disorder
Usual Initial Dosage
Mopart should be administered as a single daily dose, usually in the morning, with or without food. Mopart may be administered either daily throughout the menstrual cycle or limited to the luteal phase of the menstrual cycle, depending on physician assessment. The recommended initial dose is 12.5 mg/day. In clinical trials, both 12.5 mg/day and 25 mg/day were shown to be effective. Dose changes should occur at intervals of at least 1 week.
Patients should be cautioned that Mopart should not be chewed or crushed, and should be swallowed whole.
Maintenance/Continuation Therapy
The effectiveness of Mopart for a period exceeding 3 menstrual cycles has not been systematically evaluated in controlled trials. However, women commonly report that symptoms worsen with age until relieved by the onset of menopause. Therefore, it is reasonable to consider continuation of a responding patient. Patients should be periodically reassessed to determine the need for continued treatment.
Special Populations
Treatment of Pregnant Women During the Third Trimester
Neonates exposed to Mopart and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. When treating pregnant women with Mopart during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.
Dosage for Elderly or Debilitated Patients, and Patients With Severe Renal or Hepatic Impairment
The recommended initial dose of Mopart is 12.5 mg/day for elderly patients, debilitated patients, and/or patients with severe renal or hepatic impairment. Increases may be made if indicated. Dosage should not exceed 50 mg/day.
Switching a Patient to or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Mopart. Conversely, at least 14 days should be allowed after stopping Mopart before starting an MAOI intended to treat psychiatric disorders.
Use of Mopart With Other MAOIs, Such as Linezolid or Methylene Blue
Do not start Mopart in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered.
In some cases, a patient already receiving therapy with Mopart may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, Mopart should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Mopart may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Mopart is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use.
Discontinuation of Treatment With Mopart
Symptoms associated with discontinuation of immediate-release Mopart hydrochloride or Mopart have been reported. Patients should be monitored for these symptoms when discontinuing treatment, regardless of the indication for which Mopart is being prescribed. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
More about Mopart (Mopart)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 32 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Mopart controlled-release tablets
- Mopart
- Mopart (Advanced Reading)
- Other brands: Mopart, Pexeva
Professional resources
- Mopart (FDA)
- Mopart Hydrochloride (AHFS Monograph)
Other formulations
- Paxil
Related treatment guides
- Depression
- Generalized Anxiety Disorder
- Anxiety
- Dysautonomia
- Major Depressive Disorder
- More (6) »
What other drugs will affect Mopart?
Taking this medicine with other drugs that make you sleepy can worsen this effect. Ask your doctor before taking Mopart with a sleeping pill, narcotic pain medicine, muscle relaxer, or medicine for anxiety, depression, or seizures.
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Mopart, especially:
-
atomoxetine, cimetidine (Tagamet), metoprolol, procyclidine, St. John's wort, tamoxifen;
-
tryptophan (sometimes called L-tryptophan);
-
a blood thinner (warfarin, Coumadin, Jantoven);
-
heart rhythm medicine;
-
HIV or AIDS medications;
-
narcotic pain medicine - fentanyl, tramadol;
-
medicine to treat mood disorders, thought disorders, or mental illness - such as lithium, other antidepressants, or antipsychotics;
-
migraine headache medicine - sumatriptan, rizatriptan, zolmitriptan, and others; or
-
seizure medicine - carbamazepine, phenytoin.
This list is not complete. Other drugs may interact with Mopart, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Mopart interactions
No drug-drug interaction studies have been conducted with Mopart.
Potential for Mopart to Affect Other Drugs
Mopart is a strong CYP2D6 inhibitor. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that Mopart can inhibit the metabolism of drugs metabolized by CYP2D6. Table 2 contains examples of drugs with a metabolism that may be affected by co-administration with Mopart. 10
Table 2 : Effects of Mopart on Other Drugs
Concomitant Drug Name | Effect of Mopart on Other Drugs | Clinical Recommendations |
Thioridazine | Increased plasma concentrations of thioridazine | Concomitant use of thioridazine and Mopart is contraindicated. |
Potential QTc prolongation | ||
Pimozide | Increased plasma concentrations of pimozide. Potential QTc prolongation | Concomitant use of pimozide and Mopart is contraindicated. |
Tamoxifen | Reduced plasma concentrations of active tamoxifen metabolite | Consider avoiding concomitant use of tamoxifen and Mopart. |
Tricyclic Antidepressant (TCA) (e.g., Desipramine) | Increased plasma concentrations and elimination half-life | Plasma TCA concentrations may need to be monitored and the dose of TCA may need to be reduced if a TCA is co-administered with Mopart. Monitor tolerability. |
Risperidone | Increased plasma concentrations of risperidone | A lower dosage of risperidone may be necessary. Monitor tolerability. |
Atomoxetine | Increased exposure of atomoxetine | A lower dosage of atomoxetine may be necessary. Monitor tolerability. |
Drugs Highly Bound to Plasma Protein (e.g., Warfarin) | Increased free plasma concentrations | The dosage of warfarin may need to be reduced. Monitor tolerability and the International Normalized Ratio. |
Digoxin | Decreased plasma concentrations of digoxin | Dosage of digoxin may need to be increased. Monitor digoxin concentrations and clinical effect. |
Theophylline | Increased plasma concentrations of theophylline | Dosage of theophylline may need to be decreased. Monitor theophylline concentrations and tolerability. |
Use caution if co-administering Mopart with other drugs that are metabolized by CYP2D6, including nortriptyline, amitriptyline, imipramine, desipramine, fluoxetine, phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).
Potential for Other Drugs to Affect Mopart
The metabolism and pharmacokinetics of Mopart may be affected by the induction and inhibition of drug metabolizing enzymes such as CYP2D6. Table 3 contains a list of drugs that may affect the pharmacokinetics of Mopart when administered concomitantly.
Table 3 : Effects of Other Drugs on Mopart
Concomitant Drug Name | Effect of Concomitant Drug on Mopart | Clinical Recommendations |
Phenobarbital | Decreased Mopart exposure | No dose adjustment for Mopart. |
Phenytoin | Decreased Mopart exposure | Monitor clinical effect of Mopart. |
Fosamprenavir/ Ritonavir | Decreased plasma concentration of Mopart | |
Cimetidine | Increased plasma concentration of Mopart |
Use caution if co-administering Mopart with other drugs that inhibit CYP2D6 (e.g., quinidine).
Other Potentially Significant Drug Interactions
Monoamine Oxidase Inhibitors (MAOIs)
Serious adverse reactions such as serotonin syndrome have been reported in patients receiving a concomitant SSRI and MAOI, in patients started on an SSRI who recently received an MAOI and in patients started on an MAOI who recently received an SSRI. Therefore, concomitant use of MAOIs with Mopart or use of Mopart and an MAOI within 14 days of each other is contraindicated.
Serotonergic Drugs
If concomitant use of Mopart with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) is clinically warranted, consider the increased risk of serotonin syndrome and carefully observe the patient, particularly during treatment initiation.
An interaction between Mopart and tryptophan may occur when they are co-administered. Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking Mopart. Consequently, concomitant use of Mopart with tryptophan is not recommended.
If concomitant use of Mopart with a serotonergic drug is warranted, carefully observe the patient, particularly during treatment initiation. There have been postmarketing reports of serotonin syndrome with the use of an SSRI and a triptan.
Mopart contains Paroxetine, which is also the active ingredient in other drugs. The concomitant use of Mopart with other Mopart products is not recommended.
Drugs that Interfere with Homeostasis (e.g., NSAIDs, Aspirin, and Warfarin)
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs are co-administered with NSAIDs, aspirin, and warfarin or other drugs that affect coagulation. There may be a pharmacodynamic interaction between Mopart and warfarin that causes an increased bleeding diathesis despite unaltered prothrombin time. Carefully monitor patients receiving warfarin therapy when Mopart is initiated or discontinued.
References
- DailyMed. "PAROXETINE MESYLATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "41VRH5220H: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Cytochrome P-450 CYP2D6 Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Mopart are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mopart. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yet3 consumers reported doses
What doses of Mopart drug you have used?The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Mopart drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
Users | % | ||
---|---|---|---|
11-50mg | 2 | 66.7% | |
1-5mg | 1 | 33.3% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology